Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus BCG vs BCG alone in high-risk non-muscle invasive bladder cancer (BCG-naive)
2017-004512-19Phase 3Active
- Sponsor
- Unicancer
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in bladder cancer (2 arms), sponsored by Unicancer. Primary endpoint: Recurrence-free survival. Started Jul 2018; status: active.
02
Drugs
atezolizumab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2017-004512-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004512-19.